Lexology October 24, 2024
McGuireWoods LLP

On Sept. 18, 2024, the U.S. Food & Drug Administration (FDA) issued a final guidance document titled “Conducting Clinical Trials With Decentralized Elements, Guidance for Industry, Investigators, and Other Interested Parties”(CTDE guidance). The final guidance, which builds upon a prior draft guidance document issued in May 2023, provides valuable insight into a host of issues implicated by decentralized clinical trials (DCTs). It also reflects the FDA’s continued support for well designed and implemented DCTs and underscores the benefits that trials with decentralized elements can provide to trial participants, industry members and healthcare consumers. This article provides an overview of the guidance and discusses key takeaways for industry members, investors and other stakeholders.

Decentralized Clinical Trials

While DCTs are not new...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Clinical Trials, FDA, Govt Agencies, Trends
Related Articles:
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article